| CD45_RAT |
Rattus norvegicus |
|
CD45_RAT is differentially expressed in 35 experiments [35 up/34 dn]: 26 organism parts: kidney [0 up/2 dn], liver [1 up/0 dn], ...; 6 disease states: normal [1 up/3 dn], breast cancer [0 up/1 dn], ...; 4 cell types, 1 cell lines, 11 compound treatments and 7 other conditions. |
| CD45, CD45_RAT, L-CA, Ptprc |
|
clr-1 (Caenorhabditis elegans)
Ptp69D (Drosophila melanogaster)
Ptprc (Mus musculus)
PTPRC (Homo sapiens)
(Compare orthologs)
|
|
|
| Dual-specific/protein-tyrosine phosphatase, conserved region, Fibronectin, type III, Fibronectin, type III-like fold, Protein-tyrosine phosphatase, receptor/non-receptor type, Protein-tyrosine phosphatase, active site |
|
|
| B cell receptor signaling pathway, T cell proliferation, T cell receptor signaling pathway, cell surface, external side of plasma membrane |
|
|
|
P04157
Q5R3Z3
Q5R3Z4
Q6LDZ3
Q9JK90
Q5R3Z5
|
|
|
|
ENSRNOG00000000655
|
|
|
| Factor Value |
Factor |
Up/Down |
Legend: - number of studies the gene is up/down in
|
|
Normal
|
Disease state |
|
|
Kidney
|
Organism part |
|
|
Biological replicate 3
|
Replicate |
|
|
Liver
|
Organism part |
|
|
P15
|
Developmental stage |
|
|
P30
|
Developmental stage |
|
|
Spleen
|
Organism part |
|
|
Neurointermediate lobe
|
Organism part |
|
|
Spinal cord (T10)
|
Organism part |
|
|
Cerebral cortex
|
Organism part |
|
|
Thymus
|
Organism part |
|
|
Technical replicate 1
|
Replicate |
|
|
Bone marrow
|
Organism part |
|
|
Genestein
|
Compound treatment |
|
|
Supraoptic nucleus
|
Organism part |
|
|
Cerebellum
|
Organism part |
|
|
Diethylstilbestrol
|
Compound treatment |
|
|
Control
|
Compound treatment |
|
|
Instillation
|
Clinical treatment |
|
|
Inhalation
|
Clinical treatment |
|
|
Aortic banding
|
Clinical treatment |
|
|
None
|
Clinical treatment |
|
|
Alveolar epithelial type II
|
Cell type |
|
|
Alveolar epithelial type I
|
Cell type |
|
|
Breast cancer
|
Disease state |
|
|
N-methyl-N-nitrosurea
|
Compound treatment |
|
|
Peritoneal fat
|
Organism part |
|
|
Bisphenol A
|
Compound treatment |
|
|
Spermatid
|
Cell type |
|
|
Sertoli cell
|
Cell type |
|
|
Untreated
|
Protocol type |
|
|
Paraventricular nucleus
|
Organism part |
|
|
Mild spinal cord injury
|
Disease state |
|
|
Moderate spinal cord injury
|
Disease state |
|
|
Organism_part
|
Material type |
|
|
Cell
|
Material type |
|
|
SCN2.2
|
Cell line |
|
|
Spinal cord
|
Organism part |
|
|
Oculomotor nucleus
|
Organism part |
|
|
Endothelial cell
|
Organism part |
|
|
Dorsal striatum
|
Organism part |
|
|
Clofibrate
|
Compound treatment |
|
|
None
|
Injury |
|
|
Spinal cord contusion
|
Injury |
|
|
Av-fistula - sham
|
Clinical treatment |
|
|
Spinal cord (T9)
|
Organism part |
|
|
None
|
Compound treatment |
|
|
Bis-(2-chloroethyl) sulfide
|
Compound treatment |
|
|
Nucleus accumbens whole
|
Organism part |
|
|
Tibialis anterior skeletal mus...
|
Organism part |
|
|
Extraocular skeletal muscle
|
Organism part |
|
|
Diethylhexylphthalate
|
Compound treatment |
|
|
Nucleus accumbens core
|
Organism part |
|
|
Experimental autoimmune enceph...
|
Disease state |
|
|
Frontal cortex
|
Organism part |
|
|
Sulphated cholecystokinin-8
|
Compound treatment |
|
|
Ventral striatum
|
Organism part |
|
|
17a-ethynylestradiol
|
Compound treatment |
|
|
Proximal small intestine
|
Organism part |
|
|
Primary cortex neuron
|
Organism part |
|
|
Spermatogonia
|
Target cell type |
|
|
Hippocampus
|
Organism part |
|
|
Ischemia
|
Disease state |
|
|
Ischemia followed by reperfusi...
|
Clinical treatment |
|
|
Sham surgery
|
Clinical treatment |
|
|
|
|
|
Processing time: 0.114 secs.